Scholars@Duke
Karen Elizabeth Welty-Wolf

Karen Elizabeth Welty-Wolf

Professor of Medicine
Medicine, Pulmonary, Allergy, and Critical Care Medicine
welty001@mc.duke.edu
Duke Box 3518, Durham, NC 27710
0570 Clin Res II, Durham, NC 27710

Overview

Dr. Welty-Wolf studies (1) pathophysiology and treatment of acute lung injury and (2) multiple organ failure and disordered energy metabolism in sepsis. Injury models include hyperoxic lung injury and ARDS with multiple organ failure due to sepsis. In addition to evaluating mechanisms of lung injury in sepsis, current studies are being conducted to evaluate the potential role of monoclinal antibodies to neutrophil adhesion molecules in the prevention of this injury. Other sepsis work includes evaluating mechanisms of oxidative damage to mitochondria. Additional research efforts include evaluating the use of human recombinant manganese superoxide dismutase in preventing hyperoxic lung injury.

Current Appointments & Affiliations

Professor of Medicine · 2017 - Present Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine

Recent Publications

Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association.

Journal Article Circulation · November 7, 2023 There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic ... Full text Link to item Cite

The Eyes Have It-for Idiopathic Pulmonary Fibrosis: a Preliminary Observation.

Journal Article Pulm Ther · September 2022 INTRODUCTION: The disease origins of idiopathic pulmonary fibrosis (IPF), which occurs at higher rates in certain races/ethnicities, are not understood. The highest rates occur in white persons of European descent, particularly those with light skin, who a ... Full text Open Access Link to item Cite

Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis.

Journal Article iScience · January 21, 2022 The preclinical model of bleomycin-induced lung fibrosis is useful to study mechanisms related to human pulmonary fibrosis. Using BLM in mice, we find low HO-1 expression. Although a unique Rhenium-CO-releasing molecule (ReCORM) up-regulates HO-1, NRF-1, C ... Full text Link to item Cite
View All Publications

Recent Grants

A Phase II Study of Inhaled Carbon Monoxide for the Treatment of ARDS

Clinical TrialPrincipal Investigator · Awarded by Weill Medical College of Cornell University · 2018 - 2024

A Phase 1b Study of Inhaled CO for the Treatment of Sepsis-Induced ARDS

Clinical TrialPrincipal Investigator · Awarded by Weill Medical College of Cornell University · 2022 - 2024

Interdisciplinary Training Program in Lung Disease

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2009 - 2021

View All Grants

Education, Training & Certifications

Duke University · 1986 M.D.